Prosecution Insights
Last updated: April 19, 2026
Application No. 17/482,364

Post Cov19 Vaccine Remedies

Non-Final OA §112
Filed
Sep 22, 2021
Examiner
WEDDINGTON, KEVIN E
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Iprx LLC
OA Round
3 (Non-Final)
75%
Grant Probability
Favorable
3-4
OA Rounds
2y 7m
To Grant
85%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allow Rate
1086 granted / 1442 resolved
+15.3% vs TC avg
Moderate +10% lift
Without
With
+9.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
33 currently pending
Career history
1475
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
25.4%
-14.6% vs TC avg
§102
17.7%
-22.3% vs TC avg
§112
27.1%
-12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1442 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-3 are presented for examination. Applicant’s request for continued examination filed February 11, 2026 has been received and entered. Applicant’s substituted specification and marked-up specification filed March 12, 2026 have been received and entered. Claims 1 and 2 are withdrawn from consideration as being drawn to the non-elected invention (37 CFR.142(b)). It appears the inventor(s) filed the current application pro se (i.e., without the benefit of representation by a registered patent practitioner). While inventors named as applicants in a patent application may prosecute the application pro se, lack of familiarity with patent examination practice and procedure may result in missed opportunities in obtaining optimal protection for the invention disclosed. The inventor(s) may wish to secure the services of a registered patent practitioner to prosecute the application, because the value of a patent is largely dependent upon skilled preparation and prosecution. The Office cannot aid in selecting a patent practitioner. A listing of registered patent practitioners is available at https://oedci.uspto.gov/OEDCI/. Applicants may also obtain a list of registered patent practitioners located in their area by writing to Mail Stop OED, Director of the U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Specification The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant’s use. Arrangement of the Specification As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase “Not Applicable” should follow the section heading: (a) TITLE OF THE INVENTION. (b) CROSS-REFERENCE TO RELATED APPLICATIONS. (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT. (d) THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT. (e) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A READ-ONLY OPTICAL DISC, AS A TEXT FILE OR AN XML FILE VIA THE PATENT ELECTRONIC SYSTEM. (f) STATEMENT REGARDING PRIOR DISCLOSURES BY THE INVENTOR OR A JOINT INVENTOR. (g) BACKGROUND OF THE INVENTION. (1) Field of the Invention. (2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98. (h) BRIEF SUMMARY OF THE INVENTION. (i) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S). (j) DETAILED DESCRIPTION OF THE INVENTION. (k) CLAIM OR CLAIMS (commencing on a separate sheet). (l) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet). (m) SEQUENCE LISTING. (See MPEP § 2422.03 and 37 CFR 1.821 - 1.825). A “Sequence Listing” is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if the required “Sequence Listing” is not submitted as an electronic document either on read-only optical disc or as a text file via the patent electronic system. The disclosure (substituted specification) is objected to because of the following informalities: On page 12, sections 0028 and 0029, claims should be on a separate sheet. Note those claims were cancelled in the amendment filed November 7, 2024 and new claims 3-5 were entered. Note the amendment filed November 23, 2025 cancelled claims 3-5 and presented claims 1-3 (now pending). Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 3 is again rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a New Matter rejection. The New Matter rejection is hereby MAINTAINED until the applicant perform the suggestion as set forth in the Objection to the Specification, above supra, is complete. Claim 3 is not allowed. The rejection under 35 USC 112(b) or 35 USC 112 (pre-AIA ), first paragraph (New Matter) is adhered to. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 3 is again rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The rejection under 35 USC 112(b) or 35 USC 112 (pre-AIA ), second paragraph is hereby MAINTAINED due to applicant not responding to the rejection. Claim 3 is not allowed. The rejection made under 35 USC 112(b) or 35 USC 112 (pre-AIA ), second paragraph is adhered to. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KEVIN E WEDDINGTON whose telephone number is (571)272-0587. The examiner can normally be reached M-F 1:30-10:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeff Lundgren can be reached at 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. KEVIN E. WEDDINGTON Primary Examiner Art Unit 1629 /KEVIN E WEDDINGTON/Primary Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Sep 22, 2021
Application Filed
Sep 19, 2023
Response after Non-Final Action
Jun 11, 2024
Response Filed
Sep 03, 2024
Response Filed
Jan 09, 2025
Non-Final Rejection — §112
Jan 24, 2025
Response Filed
Jan 24, 2025
Response after Non-Final Action
Apr 01, 2025
Examiner Interview Summary
Apr 01, 2025
Applicant Interview (Telephonic)
Apr 25, 2025
Response Filed
Apr 25, 2025
Response after Non-Final Action
May 07, 2025
Response Filed
May 07, 2025
Response after Non-Final Action
Jul 10, 2025
Response after Non-Final Action
Jul 10, 2025
Response Filed
Sep 29, 2025
Response Filed
Jan 29, 2026
Final Rejection — §112
Feb 11, 2026
Request for Continued Examination
Feb 12, 2026
Response after Non-Final Action
Mar 11, 2026
Applicant Interview (Telephonic)
Mar 11, 2026
Examiner Interview Summary
Mar 26, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600696
NOVEL AROMATIC COMPOUNDS
2y 5m to grant Granted Apr 14, 2026
Patent 12599587
CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
2y 5m to grant Granted Apr 14, 2026
Patent 12594284
COMBINATION OF MICRONUTRIENTS TO STIMULATE THE ENDOGENOUS PRODUCTION OF HYDROGEN SULFIDE (H2S)
2y 5m to grant Granted Apr 07, 2026
Patent 12589085
USE OF DIAMINOGUANIDINE DERIVATIVE AND FEED COMPOSITION THEREOF IN PREPARATION OF VETERINARY DRUG
2y 5m to grant Granted Mar 31, 2026
Patent 12589086
COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
75%
Grant Probability
85%
With Interview (+9.7%)
2y 7m
Median Time to Grant
High
PTA Risk
Based on 1442 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month